Navigation Links
Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
Date:9/5/2007

U.S. Biogeneric Agents to Reach $2 Billion in Sales by 2016, According to a

New Report from Decision Resources

WALTHAM, Mass., Sept. 5 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen, the leading manufacturer of biologic agents with biologic sales of more than $14 billion in 2006, and Genentech, the second leading biologics manufacturer with biologic sales of more than $9 billion in 2006, are bracing themselves for heavy pressure from biogeneric manufacturers. According to the new special report entitled Biogenerics 2007- 2016: Physician and Payer Acceptance Fuels Brand Erosion, Amgen products such as Enbrel, Epogen and Neupogen will be eroded by biogeneric sales in both the United States and Europe. In fact, on August 31, 2007, European regulators approved Sandoz's biogeneric epoetin alfa for patients with renal anemia and those receiving chemotherapy. Genentech products such as Rituxan/MabThera and Herceptin represent windfall opportunities for biogeneric hopefuls.

The report also reveals that, with the launch of biogeneric TNF-alpha inhibitors in 2012, the U.S. biogeneric market will expand substantially through 2016 and reach a total of more than $2 billion in annual sales.

"This growth in the U.S. biogeneric market will be driven by biogeneric TNF-alpha inhibitors for rheumatoid arthritis, which we project will generate $700 million in sales by 2016, and will be supported by biogeneric versions of interferon-betas for multiple sclerosis, Herceptin for breast cancer, and ESPs for chemotherapy-induced anemia, each of which will post more than $250 million in 2016 U.S. sales," said Andrew Merseth, analyst at Decision Resources.

About Biogenerics 2007-2016: Physician and Payer Acceptance Fuels Brand Erosion

Biogenerics 2007-2016: Physician and Payer Acceptance Fuels Brand Erosion covers 13 key biologic brands used in eight indications and includes more primary research than any other report produced by Decision Resources. It includes surveys of 317 specialists from the United States, France, and Germany as well as 40 U.S. HMO pharmacy directors. The report includes a 10- year annualized forecast for the 13 key brands and for their biogeneric competition, and provides a framework for forecasting other biogenerics.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Genentechs Winning Streak
2. TeraMedica embraces open source project
3. Center for Technology Transfer embraces "Cleantech"
4. Wisconsin Film Festival embraces new online ticket ordering system
5. Wisconsin Historical Society Embraces New Web Site Technology
6. Chippewa Valley Embraces Nanotechnology
7. Wisconsin early-stage companies must position themselves to get capital
8. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
9. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
10. Cellular Dynamics hits market with UW research heavyweights
11. Governors Growth Council hopes to go light on paperwork and heavy on ideas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 05, 2016 , ... CereScan, ... the National Stroke Association during National Stroke Awareness Month in May. An ... pages throughout the month. CereScan will donate $1 up to a maximum ...
(Date:5/4/2016)... ... May 04, 2016 , ... The Children’s Tumor Foundation announced its annual month-long ... grow on nerves throughout the body. It affects 1 in 3,000 people of all ... during the month of May, as well as online activities, Neurofibromatosis Awareness Month and ...
(Date:5/3/2016)... PUNE, India , May 3, 2016 ... Type (DNA Chip (Genomics, Drug Discovery, Gene ... Chips), End user (Academics Institutes, Diagnostics Centers), ... 2020" published by MarketsandMarkets, the market is ... 2020 from USD 7.63 Billion in 2015, ...
(Date:5/3/2016)... ... 2016 , ... Flagship Biosciences, the leader in tissue ... of Directors. Dr. Gillett recently retired from Charles River Laboratories (CRL), where, in ... Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River in 1999 through ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):